RedChip shared a 30-second investor brief on Virax Biolabs. Management discussed ViraxImmune™, an immune profiling test in development intended to assess immune dysfunction associated with post-infection conditions including Long COVID, ME/CFS, and post-treatment Lyme disease. Management noted the diagnostic gap currently facing these conditions, and discussed clinical studies informing the platform's development along with plans for U.S. commercialization. ViraxImmune™ is informed by UK NHS-linked clinical studies and independent U.S. validation work conducted at Emory University. Watch our 30-second investor brief on Virax Biolabs: https://t.co/Zz3t3rJjr8 Virax Biolabs is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN $JNJ
RedChipShare
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.